var data={"title":"Bipolar disorder in pregnant women: Treatment of mania and hypomania","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Bipolar disorder in pregnant women: Treatment of mania and hypomania</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/contributors\" class=\"contributor contributor_credentials\">Victoria Hendrick, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/contributors\" class=\"contributor contributor_credentials\">Paul Keck, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/contributors\" class=\"contributor contributor_credentials\">Louise Wilkins-Haug, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/contributors\" class=\"contributor contributor_credentials\">David Solomon, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 26, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H23370694\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Medications are commonly used to treat pregnant patients, including those with manic and hypomanic episodes [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/1\" class=\"abstract_t\">1</a>]. At least one prescription drug is taken by more than 60 percent of pregnant patients [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/2\" class=\"abstract_t\">2</a>], and psychotropic drugs are taken by 21 to 33 percent [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/3,4\" class=\"abstract_t\">3,4</a>]. </p><p>This topic discusses pharmacotherapy for pregnant patients with mania or hypomania. Treatment of bipolar major depression during pregnancy, prenatal maintenance pharmacotherapy for bipolar disorder, the teratogenic and postnatal risks of medications used for bipolar disorder, and the general treatment of mania and hypomania is discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-pregnant-women-treatment-of-major-depression\" class=\"medical medical_review\">&quot;Bipolar disorder in pregnant women: Treatment of major depression&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-women-preconception-and-prenatal-maintenance-pharmacotherapy\" class=\"medical medical_review\">&quot;Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=teratogenicity-pregnancy-complications-and-postnatal-risks-of-antipsychotics-benzodiazepines-lithium-and-electroconvulsive-therapy\" class=\"medical medical_review\">&quot;Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1029357\"><span class=\"h1\">DEFINITION OF BIPOLAR DISORDER</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bipolar disorder is characterized by episodes of mania (<a href=\"image.htm?imageKey=PSYCH%2F91106\" class=\"graphic graphic_table graphicRef91106 \">table 1</a>), hypomania (<a href=\"image.htm?imageKey=PSYCH%2F91107\" class=\"graphic graphic_table graphicRef91107 \">table 2</a>), and major depression (<a href=\"image.htm?imageKey=PSYCH%2F91398\" class=\"graphic graphic_table graphicRef91398 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/5\" class=\"abstract_t\">5</a>]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-clinical-features\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Clinical features&quot;</a> and <a href=\"topic.htm?path=bipolar-disorder-in-adults-assessment-and-diagnosis\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Assessment and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H87627918\"><span class=\"h1\">INDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pharmacotherapy is indicated for pregnant patients with manic and hypomanic episodes that are characterized by [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/6\" class=\"abstract_t\">6</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Suicidal or homicidal ideation or behavior</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Aggressive behavior</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Psychotic features (delusions or hallucinations)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Poor judgement that places the patient or others at imminent risk of being harmed</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Moderate to severe impairment of social or occupational functioning</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Involvement in pleasurable activities that have a high potential for painful consequences (eg, unrestrained buying sprees or sexual indiscretions)</p><p/><p>Medications may not be indicated for some episodes of hypomania. However, it is not clear which untreated hypomanic episodes will progress to mania that requires pharmacotherapy.</p><p class=\"headingAnchor\" id=\"H86321418\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H3324848\"><span class=\"h2\">General principles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bipolar mood episodes during pregnancy are usually treated by perinatal or general psychiatrists in collaboration with obstetricians and primary care clinicians [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/4,7-10\" class=\"abstract_t\">4,7-10</a>].</p><p>For manic and hypomanic pregnant patients, treatment is based upon randomized trials that excluded pregnant patients [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/11\" class=\"abstract_t\">11</a>], as well as observational studies, birth registries, and clinical experience [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/12\" class=\"abstract_t\">12</a>].</p><p>For pregnant bipolar patients treated with pharmacotherapy, clinicians should attempt to use [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/1,4,13,14\" class=\"abstract_t\">1,4,13,14</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drugs with fewer known teratogenic effects</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Monotherapy </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Doses at the low end of the therapeutic range</p><p/><p>The risks of teratogenic effects from medications commonly used to treat bipolar disorder are discussed separately. (See <a href=\"topic.htm?path=teratogenicity-pregnancy-complications-and-postnatal-risks-of-antipsychotics-benzodiazepines-lithium-and-electroconvulsive-therapy\" class=\"medical medical_review\">&quot;Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy&quot;</a>.)</p><p>For pregnant patients with bipolar mood episodes that occur during maintenance pharmacotherapy, we favor increasing the dose within the therapeutic dose range rather than starting a second medication [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/4,15,16\" class=\"abstract_t\">4,15,16</a>]. This includes ensuring serum concentrations are in the therapeutic range for medications such as <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, as well as increasing the dose to achieve a higher serum level within the therapeutic range, provided that side effects do not intervene. However, many patients require medication combinations [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/9,17-19\" class=\"abstract_t\">9,17-19</a>]. </p><p>Following recovery from prenatal bipolar mood episodes with pharmacotherapy, we suggest that patients receive maintenance treatment. For patients who decline maintenance pharmacotherapy, abrupt discontinuation of medications should be avoided. Rather, clinicians should attempt to taper and discontinue drugs over the course of at least 15 days to minimize the risk of relapse, based upon observational studies [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/20\" class=\"abstract_t\">20</a>]. Prenatal maintenance pharmacotherapy and the risk of abruptly discontinuing pharmacotherapy are discussed separately. (See <a href=\"topic.htm?path=bipolar-disorder-in-women-preconception-and-prenatal-maintenance-pharmacotherapy\" class=\"medical medical_review\">&quot;Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy&quot;</a> and <a href=\"topic.htm?path=bipolar-disorder-in-women-contraception-and-preconception-assessment-and-counseling#H317273\" class=\"medical medical_review\">&quot;Bipolar disorder in women: Contraception and preconception assessment and counseling&quot;, section on 'Relapse after discontinuing pharmacotherapy'</a>.)</p><p class=\"headingAnchor\" id=\"H2001176\"><span class=\"h2\">Setting</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The setting for prenatal treatment of bipolar mood episodes depends upon the type and severity of symptoms, level of psychosocial functioning, and available support [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/15,21,22\" class=\"abstract_t\">15,21,22</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inpatient hospitalization is often required for safety and stabilization of patients with severe symptoms (eg, suicidal ideation with a specific plan or intent)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Partial hospital (day) treatment may be feasible for managing moderate symptoms (eg, suicidality that does not pose an imminent risk, such as fleeting thoughts of killing oneself with vague or nonexistent plans and no intent)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Outpatient treatment may be suitable for patients with less acute symptoms (eg, thoughts that family members would be better off if the patient was dead, with no plan or intent to commit suicide) </p><p/><p class=\"headingAnchor\" id=\"H32030536\"><span class=\"h2\">Monitoring the patient</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The psychiatric status of pregnant bipolar patients should be regularly monitored, with particular attention to suicidal ideation and psychosis [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/7,23\" class=\"abstract_t\">7,23</a>]. Patients taking medications are also assessed for therapeutic and adverse effects. In addition, serum concentrations of medications with established therapeutic levels (eg, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>) should be checked. Monitoring pregnant patients who take lithium is discussed separately. (See <a href=\"topic.htm?path=bipolar-disorder-in-women-preconception-and-prenatal-maintenance-pharmacotherapy#H328730\" class=\"medical medical_review\">&quot;Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy&quot;, section on 'Refractory patients'</a>.) </p><p>The frequency of assessing pregnant bipolar patients generally ranges from daily to monthly, depending upon the type and severity of symptoms. Hospitalized patients are monitored daily, and patients with active suicidal ideation, a specific plan, and intent to kill themselves typically require constant observation. Outpatients who have not achieved substantial improvement in the number, intensity, and frequency of symptoms are generally seen weekly; patients who have improved substantially may be seen every two to four weeks until they remit.</p><p class=\"headingAnchor\" id=\"H16652974\"><span class=\"h2\">Duration of individual drug trial</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest treating pregnant patients with mania and hypomania for three weeks before determining whether a specific drug is beneficial, based upon the duration of most randomized trials (which excluded pregnant patients) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/11\" class=\"abstract_t\">11</a>]. Response is defined as stabilizing the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of symptoms.</p><p class=\"headingAnchor\" id=\"H1302549\"><span class=\"h1\">SPECIFIC TREATMENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Despite clinical differences between mania and hypomania (eg, hypomania is less severe than mania), for the purpose of treatment these mood elevated syndromes are considered to be similar and thus treated with the same medications [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/15,21,22\" class=\"abstract_t\">15,21,22</a>].</p><p class=\"headingAnchor\" id=\"H13589500\"><span class=\"h2\">First line medications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For manic and hypomanic pregnant patients, we suggest first-generation antipsychotics, which have been widely used during pregnancy [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/4,24\" class=\"abstract_t\">4,24</a>]. We prefer <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a>, based upon its demonstrated efficacy in randomized trials (which excluded pregnant patients) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/11\" class=\"abstract_t\">11</a>], and other studies that suggest haloperidol is not associated with an increased risk of congenital anomalies [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/3,25\" class=\"abstract_t\">3,25</a>]. Using haloperidol is consistent with practice guidelines from the United Kingdom National Institute for Health and Clinical Excellence [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/23,26\" class=\"abstract_t\">23,26</a>], and haloperidol is preferred by many authorities [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/1,18,27\" class=\"abstract_t\">1,18,27</a>]. Other first-generation antipsychotics that are reasonable alternatives to haloperidol include <a href=\"topic.htm?path=chlorpromazine-drug-information\" class=\"drug drug_general\">chlorpromazine</a>, <a href=\"topic.htm?path=fluphenazine-drug-information\" class=\"drug drug_general\">fluphenazine</a>, <a href=\"topic.htm?path=perphenazine-drug-information\" class=\"drug drug_general\">perphenazine</a>, <a href=\"topic.htm?path=thiothixene-drug-information\" class=\"drug drug_general\">thiothixene</a>, and <a href=\"topic.htm?path=trifluoperazine-drug-information\" class=\"drug drug_general\">trifluoperazine</a> [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/28\" class=\"abstract_t\">28</a>]. Clinicians can expect that response to a first-generation antipsychotic will occur in approximately 50 percent of patients, based upon trials in nonpregnant patients [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/29\" class=\"abstract_t\">29</a>].</p><p>The efficacy of <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> for treating mood elevated syndromes appears to be comparable to <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a> and <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>, and superior to <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> and <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/11\" class=\"abstract_t\">11</a>]. In addition, there is more experience using haloperidol during pregnancy compared with second-generation antipsychotics, and the reproductive safety profile of haloperidol is generally regarded as superior to lithium. The efficacy of haloperidol, risperidone, olanzapine, quetiapine, and lithium (in randomized trials that excluded pregnant patients) is discussed separately, as is the reproductive safety profile of these drugs, and the dose, side effect profile (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a>), and pharmacology of haloperidol. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania&quot;</a> and <a href=\"topic.htm?path=teratogenicity-pregnancy-complications-and-postnatal-risks-of-antipsychotics-benzodiazepines-lithium-and-electroconvulsive-therapy\" class=\"medical medical_review\">&quot;Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy&quot;</a> and <a href=\"topic.htm?path=first-generation-antipsychotic-medications-pharmacology-administration-and-comparative-side-effects\" class=\"medical medical_review\">&quot;First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects&quot;</a>.)</p><p>For pregnant bipolar patients who cannot tolerate the usual minimal therapeutic dose of <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> (5 to 10 mg per day) because of extrapyramidal symptoms (EPS), we suggest cautiously reducing the dose (eg, by 1 to 2 mg per day), while closely monitoring the patient for exacerbation of mood elevated symptoms. If decreasing the dose is unfeasible or inadequate, we suggest tapering and discontinuing haloperidol over one to two weeks and at the same time starting and titrating up a low-potency agent (eg, <a href=\"topic.htm?path=chlorpromazine-drug-information\" class=\"drug drug_general\">chlorpromazine</a>) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/30\" class=\"abstract_t\">30</a>]. Haloperidol is tapered by the same amount for each dose decrease. As an example, haloperidol 8 mg per day is decreased by 2 mg per day every one to three days. The dose and side effects of chlorpromazine are discussed separately. </p><p>For pregnant patients receiving <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> who develop Parkinsonism or dystonia, a reasonable alternative to switching drugs is to add <a href=\"topic.htm?path=diphenhydramine-drug-information\" class=\"drug drug_general\">diphenhydramine</a>. Reviews suggest that the risk of teratogenicity with antihistamines such as diphenhydramine appears to be low [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/31\" class=\"abstract_t\">31</a>], and that fetal organ malformation appears to be less likely with diphenhydramine than <a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">amantadine</a>, <a href=\"topic.htm?path=benztropine-benzatropine-drug-information\" class=\"drug drug_general\">benztropine</a>, and <a href=\"topic.htm?path=trihexyphenidyl-drug-information\" class=\"drug drug_general\">trihexyphenidyl</a> [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/30,32\" class=\"abstract_t\">30,32</a>]. Additional information about the treatment of extrapyramidal symptoms and the teratogenic risks of antiparkinsonian drugs is discussed separately. (See <a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-side-effect-management#H28219024\" class=\"medical medical_review\">&quot;Pharmacotherapy for schizophrenia: Side effect management&quot;, section on 'Extrapyramidal symptoms'</a> and <a href=\"topic.htm?path=teratogenicity-pregnancy-complications-and-postnatal-risks-of-antipsychotics-benzodiazepines-lithium-and-electroconvulsive-therapy#H1564785\" class=\"medical medical_review\">&quot;Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy&quot;, section on 'Antiparkinsonian drugs used for treating extrapyramidal symptoms'</a>.) </p><p class=\"headingAnchor\" id=\"H1303216\"><span class=\"h2\">Resistant patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In our clinical experience, pregnant patients with manic and hypomanic episodes often do not respond to or tolerate <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a>. (Response is defined as stabilizing the patient&rsquo;s safety and substantial improvement in the number, intensity, and frequency of symptoms.) For these resistant patients, we suggest in order of preference <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a>, <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, or <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>, based upon their efficacy and side effects in randomized trials (that excluded pregnant patients) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/11\" class=\"abstract_t\">11</a>], as well as study findings that suggest these drugs are not associated with an increased risk of major malformations [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/19,33,34\" class=\"abstract_t\">19,33,34</a>]. Using second-generation antipsychotics during pregnancy is consistent with the practice of many perinatal psychiatrists [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/18\" class=\"abstract_t\">18</a>]. Up to 50 to 60 percent of patients may respond, based upon trials in nonpregnant patients [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/29\" class=\"abstract_t\">29</a>]. </p><p>The efficacy of <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a> and <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> appears to be superior to <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a> and <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>; quetiapine appears to be better tolerated than olanzapine; and although the efficacy of quetiapine and lithium appear comparable, quetiapine may be better tolerated [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/11\" class=\"abstract_t\">11</a>]. In addition, study findings suggest that second-generation antipsychotics are not associated with an increased risk of major malformations [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/18,19,33,34\" class=\"abstract_t\">18,19,33,34</a>], whereas lithium is generally regarded as teratogenic [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/35-37\" class=\"abstract_t\">35-37</a>]. The preference for treating pregnant bipolar patients with risperidone, quetiapine, or olanzapine rather than lithium is consistent with practice guidelines from the United Kingdom National Institute for Health and Clinical Excellence [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/23,26\" class=\"abstract_t\">23,26</a>]. &#160;</p><p>However, second-generation antipsychotics, particularly <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>, may cause metabolic complications (eg, hyperglycemia and obesity) that are associated with risks to the mother and fetus [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/38,39\" class=\"abstract_t\">38,39</a>]. These risks are discussed separately, as is monitoring of metabolic parameters in pregnant patients taking second-generation antipsychotics. (See <a href=\"topic.htm?path=bipolar-disorder-in-women-preconception-and-prenatal-maintenance-pharmacotherapy#H22544288\" class=\"medical medical_review\">&quot;Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy&quot;, section on 'Metabolic complications'</a>.)</p><p>To switch drugs, <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> is tapered and discontinued over one to two weeks while at the same time <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a> is started and titrated up. We generally taper haloperidol by the same amount for each dose decrease. As an example, haloperidol 8 mg per day is decreased by 2 mg per day, every one to three days. For resistant pregnant bipolar patients who do not respond to or tolerate treatment with one second line medication, we suggest tapering and discontinuing the failed medication over one to two weeks at the same time that another second-line medication is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease. As an example, risperidone 6 mg per day is decreased by 1 to 2 mg per day, every one to three days. </p><p>The efficacy of <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a>, <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, and <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a> for treating mood elevated syndromes (in randomized trials that excluded pregnant patients) is discussed separately, as are the doses, side effects (<a href=\"image.htm?imageKey=PSYCH%2F82533\" class=\"graphic graphic_table graphicRef82533 \">table 4</a>), pharmacology, and reproductive safety profiles. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania&quot;</a> and <a href=\"topic.htm?path=teratogenicity-pregnancy-complications-and-postnatal-risks-of-antipsychotics-benzodiazepines-lithium-and-electroconvulsive-therapy#H1561513\" class=\"medical medical_review\">&quot;Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy&quot;, section on 'Second-generation'</a> and <a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Second-generation antipsychotic medications: Pharmacology, administration, and side effects&quot;</a>.) &#160;</p><p class=\"headingAnchor\" id=\"H1303232\"><span class=\"h2\">Refractory patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based upon clinical experience, prenatal manic and hypomanic episodes generally respond to sequential trials of <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a>, <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a>, <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, and <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>. (Response is defined as stabilizing the safety of the patient, as well as substantial improvement in the number, intensity, and frequency of symptoms.) However, for refractory patients who do not respond to antipsychotics, we suggest in order of preference <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> and electroconvulsive therapy (ECT) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/40\" class=\"abstract_t\">40</a>]. For patients unresponsive to sequential trials of lithium and ECT, other options include lithium plus an antipsychotic, <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, and <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a>.</p><p class=\"headingAnchor\" id=\"H116932278\"><span class=\"h3\">Lithium</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For pregnant patients with manic episodes that do not respond to multiple antipsychotics, we suggest <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, based upon its efficacy and side effects in randomized trials (which excluded pregnant patients) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/11\" class=\"abstract_t\">11</a>]. Although lithium is generally regarded as teratogenic due to increased risks of cardiac defects (eg, Ebstein&rsquo;s anomaly) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/35-37\" class=\"abstract_t\">35-37</a>], many authorities consider the absolute risk small [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/1,4,17,32,41\" class=\"abstract_t\">1,4,17,32,41</a>]. Clinicians can expect that up to approximately 50 percent of patients will respond, based upon trials in nonpregnant patients [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/29\" class=\"abstract_t\">29</a>]. Use of lithium in pregnant patients with bipolar disorder who do not respond to antipsychotics is consistent with practice guidelines from the United Kingdom National Institute for Health and Care Excellence [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/42\" class=\"abstract_t\">42</a>].</p><p>The dose schedule for <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, use of serum concentrations to establish the proper dose, and lithium toxicity are discussed separately, as are using lithium during pregnancy and lithium&rsquo;s reproductive safety profile. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-and-lithium-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects&quot;</a> and <a href=\"topic.htm?path=bipolar-disorder-in-women-preconception-and-prenatal-maintenance-pharmacotherapy#H328730\" class=\"medical medical_review\">&quot;Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy&quot;, section on 'Refractory patients'</a> and <a href=\"topic.htm?path=teratogenicity-pregnancy-complications-and-postnatal-risks-of-antipsychotics-benzodiazepines-lithium-and-electroconvulsive-therapy#H1561534\" class=\"medical medical_review\">&quot;Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy&quot;, section on 'Lithium'</a>.)</p><p class=\"headingAnchor\" id=\"H4605992\"><span class=\"h3\">Electroconvulsive therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For pregnant patients with moderate to severe manic episodes that do not respond to sequential trials of antipsychotics and <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, we suggest electroconvulsive therapy (ECT), which is generally regarded as efficacious and safe [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/43-45\" class=\"abstract_t\">43-45</a>]. The use of ECT for pregnant bipolar patients is consistent with recommendations in multiple practice guidelines [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/7,42,46-48\" class=\"abstract_t\">7,42,46-48</a>]. </p><p>ECT is typically well tolerated and there are no absolute contraindications to ECT, even among patients whose general medical status is compromised [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/44\" class=\"abstract_t\">44</a>]. However, safety concerns regarding ECT necessitate preprocedure obstetric consultation (consistent with guideline recommendation), with emphasis upon assessing risk factors for spontaneous abortion, preterm labor, abruption, and uteroplacental insufficiency due to the association of ECT with transient increases or decreases in blood pressure and uterine contractions. The patient&rsquo;s general medical status is also evaluated; medical consultation prior to ECT is discussed separately, as is the use of ECT for patients with general medical conditions. (See <a href=\"topic.htm?path=medical-consultation-for-electroconvulsive-therapy\" class=\"medical medical_review\">&quot;Medical consultation for electroconvulsive therapy&quot;</a> and <a href=\"topic.htm?path=overview-of-electroconvulsive-therapy-ect-for-adults#H5\" class=\"medical medical_review\">&quot;Overview of electroconvulsive therapy (ECT) for adults&quot;, section on 'Patients with comorbid general medical illness'</a>.)</p><p>ECT is generally given three times per week on alternate days. Most patients regardless of indication remit with 6 to 12 treatments, but some patients require 20 or more. A review of prenatal ECT found that the mean number of treatments per ECT course was 11 [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/45\" class=\"abstract_t\">45</a>]. The number and frequency of treatments in the general use of ECT is discussed separately, as are the adjustments in ECT technique for pregnant patients. (See <a href=\"topic.htm?path=overview-of-electroconvulsive-therapy-ect-for-adults#H17\" class=\"medical medical_review\">&quot;Overview of electroconvulsive therapy (ECT) for adults&quot;, section on 'Treatment course'</a> and <a href=\"topic.htm?path=technique-for-performing-electroconvulsive-therapy-ect-in-adults#H13734882\" class=\"medical medical_review\">&quot;Technique for performing electroconvulsive therapy (ECT) in adults&quot;, section on 'Pregnancy'</a>.)</p><p>Following a course of ECT, clinicians usually prescribe maintenance pharmacotherapy. (See <a href=\"topic.htm?path=bipolar-disorder-in-women-preconception-and-prenatal-maintenance-pharmacotherapy#H51186202\" class=\"medical medical_review\">&quot;Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy&quot;, section on 'Specific drugs'</a>.)</p><p>Evidence supporting the use of ECT includes studies that found ECT is effective for mania in patients who are not pregnant. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-indications-for-and-efficacy-of-electroconvulsive-therapy-ect#H518772731\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy (ECT)&quot;, section on 'Mania'</a>.)</p><p>In addition, a review of observational studies of pregnant patients treated for mood or psychotic disorders with ECT found that among 68 cases with outcome data, at least partial remission occurred in 78 percent [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/45\" class=\"abstract_t\">45</a>]. Among the seven patients with bipolar disorder, remission occurred in five and partial remission in one. A subsequent retrospective study of 12 pregnant bipolar patients found that remission occurred in 11 (92 percent) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/49\" class=\"abstract_t\">49</a>], and a case report described a pregnant patient with manic catatonia who remitted after two ECT treatments [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/50\" class=\"abstract_t\">50</a>].</p><p>ECT during pregnancy is generally regarded as safe for the mother and fetus [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/44,51,52\" class=\"abstract_t\">44,51,52</a>]. Many authorities think that ECT poses fewer risks than untreated bipolar mood episodes and medications that are potentially teratogenic (eg, <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> and <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, and to a lesser extent <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>) [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/1,44,45,53,54\" class=\"abstract_t\">1,44,45,53,54</a>]. The reproductive safety profile of ECT is discussed separately. (See <a href=\"topic.htm?path=severe-antenatal-unipolar-major-depression-treatment#H938487983\" class=\"medical medical_review\">&quot;Severe antenatal unipolar major depression: Treatment&quot;, section on 'Electroconvulsive therapy'</a> and <a href=\"topic.htm?path=teratogenicity-pregnancy-complications-and-postnatal-risks-of-antipsychotics-benzodiazepines-lithium-and-electroconvulsive-therapy#H1561541\" class=\"medical medical_review\">&quot;Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy&quot;, section on 'Electroconvulsive therapy'</a>.)</p><p>The general adverse effects of ECT include cardiopulmonary events, aspiration pneumonia, fractures, dental and tongue injuries, headache, nausea, and cognitive impairment [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/44\" class=\"abstract_t\">44</a>]. These side effects and their management are discussed separately. (See <a href=\"topic.htm?path=overview-of-electroconvulsive-therapy-ect-for-adults#H21\" class=\"medical medical_review\">&quot;Overview of electroconvulsive therapy (ECT) for adults&quot;, section on 'Adverse effects'</a>.)</p><p class=\"headingAnchor\" id=\"H86405662\"><span class=\"h3\">Other options</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For pregnant bipolar patients with moderate to severe manic episodes that do not respond to sequential trials of antipsychotics, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, and ECT, we suggest in order of preference:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">Lithium</a><strong> plus an antipsychotic</strong> &ndash; For patients who do not respond to lithium monotherapy and decline or do not have access to ECT, we suggest adding either a first or second-generation antipsychotic to lithium, based upon randomized trials that excluded pregnant patients. (Response is defined as stabilizing the safety of the patient, as well as substantial improvement in the number, intensity, and frequency of symptoms.) For patients who do not respond to antipsychotics, lithium, and ECT, we concurrently start lithium plus an antipsychotic. </p><p/><p class=\"bulletIndent1\">No head-to-head trials have compared medication combinations consisting of <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> plus an antipsychotic; we typically use lithium plus <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a>, <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a>, <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, or <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>. The choice of an antipsychotic is based upon factors including past response to medications, side effect profiles, comorbid general medical conditions, potential for drug-drug interactions, patient preference, and cost. As an example, if the patient previously showed a modest response to haloperidol and no response to risperidone, quetiapine, or olanzapine, we would choose lithium plus haloperidol. </p><p/><p class=\"bulletIndent1\">The efficacy of <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a> plus an antipsychotic in randomized trials (that excluded pregnant patients) is discussed separately, as are the doses, side effects, pharmacology, and reproductive safety profiles. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania&quot;</a> and <a href=\"topic.htm?path=teratogenicity-pregnancy-complications-and-postnatal-risks-of-antipsychotics-benzodiazepines-lithium-and-electroconvulsive-therapy\" class=\"medical medical_review\">&quot;Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy&quot;</a> and <a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">&quot;Second-generation antipsychotic medications: Pharmacology, administration, and side effects&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Specific medication interactions that can occur may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.</p><p/><p class=\"bulletIndent1\">Refractory patients who do not respond to or tolerate one <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a><span class=\"nowrap\">/antipsychotic</span> combination should be treated with a second combination. We usually taper and discontinue the failed antipsychotic at the same time that a different antipsychotic is started and titrated up. The failed antipsychotic is generally tapered over one to two weeks by the same amount for each dose decrease (eg, <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> 8 mg per day is decreased by 2 mg per day, every one to three days). &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a><strong> or </strong><a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a><strong> (divalproex)</strong> &ndash; For pregnant patients with manic episodes, we typically avoid carbamazepine and valproate because of the risks of teratogenic and postnatal developmental effects [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/1\" class=\"abstract_t\">1</a>]. However, for patients who do not respond to sequential treatment with antipsychotics, <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, ECT, and lithium plus antipsychotics, and have previously responded to carbamazepine or valproate for preconception mood episodes, it is reasonable to use either of these antiepileptics [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/23,26\" class=\"abstract_t\">23,26</a>], both of which have demonstrated efficacy in randomized trials that did not include pregnant patients [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/11\" class=\"abstract_t\">11</a>]. The evidence of efficacy, dose, side effects, and pharmacology of carbamazepine and valproate are discussed separately, as is the management of pregnant patients receiving these drugs, and the risks of teratogenic and postnatal effects; much of this information is based upon treatment of epilepsy. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania&quot;</a> and <a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects\" class=\"medical medical_review\">&quot;Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects&quot;</a> and <a href=\"topic.htm?path=management-of-epilepsy-and-pregnancy#H8\" class=\"medical medical_review\">&quot;Management of epilepsy and pregnancy&quot;, section on 'Management during pregnancy and delivery'</a> and <a href=\"topic.htm?path=risks-associated-with-epilepsy-and-pregnancy#H4\" class=\"medical medical_review\">&quot;Risks associated with epilepsy and pregnancy&quot;, section on 'Effect of antiseizure drugs on the fetus'</a>.)</p><p/><p class=\"bulletIndent1\">Patients treated with <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> or <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> during pregnancy should also receive <a href=\"topic.htm?path=folic-acid-drug-information\" class=\"drug drug_general\">folic acid</a> 4 mg per day, which may prevent neural tube defects [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/55\" class=\"abstract_t\">55</a>]. In addition, the obstetrician should be informed to screen for teratogenic effects [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"topic.htm?path=management-of-epilepsy-and-pregnancy#H8\" class=\"medical medical_review\">&quot;Management of epilepsy and pregnancy&quot;, section on 'Management during pregnancy and delivery'</a> and <a href=\"topic.htm?path=folic-acid-supplementation-in-pregnancy#H10\" class=\"medical medical_review\">&quot;Folic acid supplementation in pregnancy&quot;, section on 'Antiepileptic drugs'</a> and <a href=\"topic.htm?path=open-neural-tube-defects-risk-factors-prenatal-screening-and-diagnosis-and-pregnancy-management\" class=\"medical medical_review\">&quot;Open neural tube defects: Risk factors, prenatal screening and diagnosis, and pregnancy management&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Valnoctamide (not available in the United States) is an analogue of <a href=\"topic.htm?path=valproate-drug-information\" class=\"drug drug_general\">valproate</a> that appears to be less teratogenic in mice than valproate, and may possibly benefit acutely manic, pregnant patients [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/56\" class=\"abstract_t\">56</a>]. A randomized trial compared adjunctive valnoctamide (400 mg three times daily) with placebo in 32 nonpregnant, manic patients treated with <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a> (1 to 4 mg per day); manic symptoms improved significantly more with adjunctive valnoctamide [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/57\" class=\"abstract_t\">57</a>]. </p><p/><p class=\"headingAnchor\" id=\"H1614170480\"><span class=\"h2\">Severe anxiety or insomnia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For pregnant patients with mania, hypomania, or mixed episodes who also suffer severe anxiety or insomnia despite ongoing pharmacotherapy, we suggest small doses of an adjunctive benzodiazepine on an as needed basis for as short a time as possible [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/1\" class=\"abstract_t\">1</a>]. We prefer the high potency compounds <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a> or <a href=\"topic.htm?path=clonazepam-drug-information\" class=\"drug drug_general\">clonazepam</a> because they have shorter half-lives than <a href=\"topic.htm?path=diazepam-drug-information\" class=\"drug drug_general\">diazepam</a> and <a href=\"topic.htm?path=chlordiazepoxide-drug-information\" class=\"drug drug_general\">chlordiazepoxide</a> and are thus less likely to accumulate over time and cause toxicity [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/1,58,59\" class=\"abstract_t\">1,58,59</a>]. <a href=\"topic.htm?path=alprazolam-drug-information\" class=\"drug drug_general\">Alprazolam</a> is generally discouraged because its short half-life can produce rebound anxiety. We generally use lorazepam (eg, 0.5 or 1 mg) because it has no active metabolites and may cross the placenta at a lower rate than other benzodiazepines [<a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/58\" class=\"abstract_t\">58</a>]. Clonazepam (eg, 0.5 or 1 mg) is preferred for patients who require a drug with a longer half-life. The teratogenicity, pregnancy complications, and postnatal risks of benzodiazepines are discussed separately. (See <a href=\"topic.htm?path=teratogenicity-pregnancy-complications-and-postnatal-risks-of-antipsychotics-benzodiazepines-lithium-and-electroconvulsive-therapy#H1561527\" class=\"medical medical_review\">&quot;Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy&quot;, section on 'Benzodiazepines'</a>.) </p><p class=\"headingAnchor\" id=\"H1828161573\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-bipolar-disorder\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Bipolar disorder&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (See <a href=\"topic.htm?path=bipolar-disorder-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Bipolar disorder (The Basics)&quot;</a> and <a href=\"topic.htm?path=reducing-the-costs-of-medicines-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Reducing the costs of medicines (The Basics)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (See <a href=\"topic.htm?path=bipolar-disorder-manic-depression-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Bipolar disorder (manic depression) (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=reducing-the-costs-of-medicines-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Reducing the costs of medicines (Beyond the Basics)&quot;</a>.)</p><p/><p>These educational materials can be used as part of psychoeducational psychotherapy. (See <a href=\"topic.htm?path=bipolar-disorder-in-adults-psychoeducation-and-other-adjunctive-maintenance-psychotherapies#H88286585\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies&quot;, section on 'Group psychoeducation'</a>.) &#160;</p><p>The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled &quot;Bipolar Disorder,&quot; which is available online at the website <a href=\"http://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml&amp;token=0tDNz8pYA0vPJ1c3GKnfXm6rR6Wn90h+lTkD0hPN0wKneShY4jnL7w6OiFvM8867fxs8Z2AHsbk+IUmVcN+gJ/p5aJLVr9XFHdaq6pnb/FI=&amp;TOPIC_ID=14647\" target=\"_blank\" class=\"external\">http://www.nimh.nih.gov/health/publications/bipolar-disorder/complete-index.shtml</a> or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.</p><p>More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).</p><p>The Depression and Bipolar Support Alliance (<a href=\"http://www.dbsalliance.org/&amp;token=t/E/KJ/vXKbS8rOg3smveJKJLyGM2L6gx6ge/jIm6bXzlDqL73YpGHmVJdDt26oj&amp;TOPIC_ID=14647\" target=\"_blank\" class=\"external\">http://www.dbsalliance.org</a> or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.</p><p>The National Alliance on Mental Illness (<a href=\"http://www.nami.org/&amp;token=0kQT3eXJw+rNOP0+8f9imR49WjqDpL2zjXCU8tX5vdg=&amp;TOPIC_ID=14647\" target=\"_blank\" class=\"external\">http://www.nami.org</a> or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.</p><p class=\"headingAnchor\" id=\"H116932847\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bipolar disorder is characterized by episodes of mania (<a href=\"image.htm?imageKey=PSYCH%2F91106\" class=\"graphic graphic_table graphicRef91106 \">table 1</a>), hypomania (<a href=\"image.htm?imageKey=PSYCH%2F91107\" class=\"graphic graphic_table graphicRef91107 \">table 2</a>), and major depression (<a href=\"image.htm?imageKey=PSYCH%2F91398\" class=\"graphic graphic_table graphicRef91398 \">table 3</a>). (See <a href=\"#H1029357\" class=\"local\">'Definition of bipolar disorder'</a> above and <a href=\"topic.htm?path=bipolar-disorder-in-adults-clinical-features#H11685824\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Clinical features&quot;, section on 'Clinical presentation'</a> and <a href=\"topic.htm?path=bipolar-disorder-in-adults-assessment-and-diagnosis#H4503550\" class=\"medical medical_review\">&quot;Bipolar disorder in adults: Assessment and diagnosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pharmacotherapy is indicated for pregnant patients with manic or hypomanic episodes that are characterized by (see <a href=\"#H87627918\" class=\"local\">'Indications'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Suicidal or homicidal ideation or behavior</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Aggressive behavior</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Psychotic features (delusions or hallucinations)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Poor judgement that places the patient or others at imminent risk of being harmed</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Moderate to severe impairment of social or occupational functioning</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Involvement in pleasurable activities that have a high potential for painful consequences (eg, unrestrained buying sprees or sexual indiscretions) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinicians treating pregnant patients with manic or hypomanic episodes should attempt to use drugs with fewer known teratogenic effects, monotherapy, and doses at the low end of the therapeutic range. An individual drug trial typically lasts three weeks before determining the medication is beneficial. (See <a href=\"#H3324848\" class=\"local\">'General principles'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For manic and hypomanic pregnant patients, we suggest first-generation antipsychotics rather than other medications (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). We prefer <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a>, but reasonable alternatives include <a href=\"topic.htm?path=chlorpromazine-drug-information\" class=\"drug drug_general\">chlorpromazine</a>, <a href=\"topic.htm?path=fluphenazine-drug-information\" class=\"drug drug_general\">fluphenazine</a>, <a href=\"topic.htm?path=perphenazine-drug-information\" class=\"drug drug_general\">perphenazine</a>, <a href=\"topic.htm?path=thiothixene-drug-information\" class=\"drug drug_general\">thiothixene</a>, and <a href=\"topic.htm?path=trifluoperazine-drug-information\" class=\"drug drug_general\">trifluoperazine</a>. (See <a href=\"#H13589500\" class=\"local\">'First line medications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For pregnant patients with manic or hypomanic episodes who do not respond to or tolerate first-generation antipsychotics, we suggest in order of preference <a href=\"topic.htm?path=risperidone-drug-information\" class=\"drug drug_general\">risperidone</a>, <a href=\"topic.htm?path=quetiapine-drug-information\" class=\"drug drug_general\">quetiapine</a>, and <a href=\"topic.htm?path=olanzapine-drug-information\" class=\"drug drug_general\">olanzapine</a>, rather than other drugs (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H1303216\" class=\"local\">'Resistant patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pregnant patients with refractory manic or hypomanic episodes that do not respond to antipsychotics are often treated with <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">lithium</a>, electroconvulsive therapy (ECT), or lithium plus an antipsychotic. (See <a href=\"#H1303232\" class=\"local\">'Refractory patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Small doses of an adjunctive benzodiazepine (eg, <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">lorazepam</a>) on an as needed basis can be helpful for severe anxiety or insomnia. (See <a href=\"#H1614170480\" class=\"local\">'Severe anxiety or insomnia'</a> above.) </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/1\" class=\"nounderline abstract_t\">Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161:608.</a></li><li class=\"breakAll\">Newport DJ, Fernandez SV, Juric S, Stowe ZN. Psychopharmacology during pregnancy and lactation. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.1373.</li><li class=\"breakAll\">Owen JA. Psychopharmacology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Inc., Washington, DC 2011. p.957.</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/4\" class=\"nounderline abstract_t\">ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008; 111:1001. Reaffirmed 2018.</a></li><li class=\"breakAll\">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/6\" class=\"nounderline abstract_t\">Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol 2011; 117:961.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/7\" class=\"nounderline abstract_t\">Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/8\" class=\"nounderline abstract_t\">Jones I, Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry 2005; 186:453.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/9\" class=\"nounderline abstract_t\">Burt VK, Bernstein C, Rosenstein WS, Altshuler LL. Bipolar disorder and pregnancy: maintaining psychiatric stability in the real world of obstetric and psychiatric complications. Am J Psychiatry 2010; 167:892.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/10\" class=\"nounderline abstract_t\">Shah N. Mood disorder in the perinatal period. BMJ 2012; 344:e1209.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/11\" class=\"nounderline abstract_t\">Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378:1306.</a></li><li class=\"breakAll\">Frey BN, Macritchie KA, Soares CN, Steiner M. Bipolar disorder in women. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M (Eds), Wiley-Blackwell, West Sussex 2010. p.463.</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/13\" class=\"nounderline abstract_t\">Cohen LS. Treatment of bipolar disorder during pregnancy. J Clin Psychiatry 2007; 68 Suppl 9:4.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/14\" class=\"nounderline abstract_t\">Bergink V, Bouvy PF, Vervoort JS, et al. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry 2012; 169:609.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/15\" class=\"nounderline abstract_t\">American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1.</a></li><li class=\"breakAll\">American Psychiatric Association Practice Guideline for the Treatment of Patients with Bipolar Disorder, Second Edition, 2002. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf (Accessed on January 16, 2017).</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/17\" class=\"nounderline abstract_t\">Cohen LS, Wang B, Nonacs R, et al. Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 2010; 33:273.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/18\" class=\"nounderline abstract_t\">Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164:1214.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/19\" class=\"nounderline abstract_t\">McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66:444.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/20\" class=\"nounderline abstract_t\">Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007; 164:1817.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/21\" class=\"nounderline abstract_t\">Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10:85.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/22\" class=\"nounderline abstract_t\">Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11:225.</a></li><li class=\"breakAll\">National Institute for Health and Clinical Excellence. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38, 2006. http://www.nice.org.uk/ (Accessed on March 07, 2012).</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/24\" class=\"nounderline abstract_t\">Reis M, K&auml;ll&eacute;n B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008; 28:279.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/25\" class=\"nounderline abstract_t\">Diav-Citrin O, Shechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005; 66:317.</a></li><li class=\"breakAll\">National Institute for Health and Clinical Excellence. NICE clinical guideline 45. Antenatal and postnatal mental health: Clinical management and service guidance. April 2007 http://www.nice.org.uk/CG045 (Accessed on January 01, 2012).</li><li class=\"breakAll\">Janicak PG, Marder SR, Pavuluri MN. Principles and Practice of Psychopharmacotherapy, Fifth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.367.</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/28\" class=\"nounderline abstract_t\">Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010; 36:518.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/29\" class=\"nounderline abstract_t\">Smith LA, Cornelius V, Warnock A, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9:551.</a></li><li class=\"breakAll\">Burt VK, Stein K. Treatment of women. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales RE, Yodofsky SC, Gabbard GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.1489.</li><li class=\"breakAll\">Briggs GG, Freeman RK, Yaffe SJ. Diphenhydramine. In: Drugs in Pregnancy and Lactation, 9th edition, Lippincott Williams &amp; Wilkins, Philadelphia 2009. p.844.</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/32\" class=\"nounderline abstract_t\">Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/33\" class=\"nounderline abstract_t\">Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009; 15:183.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/34\" class=\"nounderline abstract_t\">Coppola D, Russo LJ, Kwarta RF Jr, et al. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007; 30:247.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/35\" class=\"nounderline abstract_t\">Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract 2005; 11:177.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/36\" class=\"nounderline abstract_t\">Kloos AL, Dubin-Rhodin A, Sackett JC, et al. The impact of mood disorders and their treatment on the pregnant woman, the fetus, and the infant. Curr Psychiatry Rep 2010; 12:96.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/37\" class=\"nounderline abstract_t\">Galbally M, Snellen M, Walker S, Permezel M. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010; 44:99.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/38\" class=\"nounderline abstract_t\">De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8:114.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/39\" class=\"nounderline abstract_t\">Choong E, Bondolfi G, Etter M, et al. Psychotropic drug-induced weight gain and other metabolic complications in a Swiss psychiatric population. J Psychiatr Res 2012; 46:540.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/40\" class=\"nounderline abstract_t\">Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 2002; 47:426.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/41\" class=\"nounderline abstract_t\">Gentile S. Drug treatment for mood disorders in pregnancy. Curr Opin Psychiatry 2011; 24:34.</a></li><li class=\"breakAll\">National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance. NICE clinical guideline 192. December 2014. http://www.nice.org.uk/guidance/cg192 (Accessed on August 27, 2015).</li><li class=\"breakAll\">Stewart DE, Vigod SN, Stotland NL. Obstetrics and gynecology. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Inc, Washington, DC 2011. p.797.</li><li class=\"breakAll\">American Psychiatric Association. Use of electroconvulsive therapy in special populations. In: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, Second Edition, American Psychiatric Association, Washington, DC 2001. p.31.</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/45\" class=\"nounderline abstract_t\">Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009; 71:235.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/46\" class=\"nounderline abstract_t\">Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 Suppl 3:5.</a></li><li class=\"breakAll\">American Psychiatric Association Practice Guideline for the Treatment of Patients With Bipolar Disorder Second Edition http://psychiatryonline.org/guidelines.aspx (Accessed on December 19, 2011).</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/48\" class=\"nounderline abstract_t\">Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013; 15:1.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/49\" class=\"nounderline abstract_t\">Bulbul F, Copoglu US, Alpak G, et al. Electroconvulsive therapy in pregnant patients. Gen Hosp Psychiatry 2013; 35:636.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/50\" class=\"nounderline abstract_t\">Pinna M, Manchia M, Pillai G, et al. Efficacy and safety of electroconvulsive therapy in the first trimester of pregnancy: a case of severe manic catatonia. Bipolar Disord 2015; 17:567.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/51\" class=\"nounderline abstract_t\">American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry 2010; 167:1.</a></li><li class=\"breakAll\">American Psychiatric Association Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition http://psychiatryonline.org/guidelines.aspx (Accessed on December 19, 2011).</li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/53\" class=\"nounderline abstract_t\">Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994; 45:444.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/54\" class=\"nounderline abstract_t\">Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001; 46:710.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/55\" class=\"nounderline abstract_t\">Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003; 61:S23.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/56\" class=\"nounderline abstract_t\">Radatz M, Ehlers K, Yagen B, et al. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res 1998; 30:41.</a></li><li><a href=\"https://www.uptodate.com/contents/bipolar-disorder-in-pregnant-women-treatment-of-mania-and-hypomania/abstract/57\" class=\"nounderline abstract_t\">Bersudsky Y, Applebaum J, Gaiduk Y, et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord 2010; 12:376.</a></li><li class=\"breakAll\">Burt VK, Suri R, Edelstein C. Treatment of women. In: The American Psychiatric Publishing Textbook of Psychiatry, Sixth Edition, Hales RE, Yudofsky SC, Roberts LW (Eds), American Psychiatric Publishing, Washington, DC 2014. p.1319.</li><li class=\"breakAll\">Zappert LN, Rasgon NL. Management of bipolar disorders in women. In: Handbook of Diagnosis and Treatment of Bipolar Disorders, Ketter TA (Ed), American Psychiatric Publishing, Inc., Washington, DC 2010. p.425.</li></ol></div><div id=\"topicVersionRevision\">Topic 14647 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H116932847\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H23370694\" id=\"outline-link-H23370694\">INTRODUCTION</a></li><li><a href=\"#H1029357\" id=\"outline-link-H1029357\">DEFINITION OF BIPOLAR DISORDER</a></li><li><a href=\"#H87627918\" id=\"outline-link-H87627918\">INDICATIONS</a></li><li><a href=\"#H86321418\" id=\"outline-link-H86321418\">MANAGEMENT</a><ul><li><a href=\"#H3324848\" id=\"outline-link-H3324848\">General principles</a></li><li><a href=\"#H2001176\" id=\"outline-link-H2001176\">Setting</a></li><li><a href=\"#H32030536\" id=\"outline-link-H32030536\">Monitoring the patient</a></li><li><a href=\"#H16652974\" id=\"outline-link-H16652974\">Duration of individual drug trial</a></li></ul></li><li><a href=\"#H1302549\" id=\"outline-link-H1302549\">SPECIFIC TREATMENTS</a><ul><li><a href=\"#H13589500\" id=\"outline-link-H13589500\">First line medications</a></li><li><a href=\"#H1303216\" id=\"outline-link-H1303216\">Resistant patients</a></li><li><a href=\"#H1303232\" id=\"outline-link-H1303232\">Refractory patients</a><ul><li><a href=\"#H116932278\" id=\"outline-link-H116932278\">- Lithium</a></li><li><a href=\"#H4605992\" id=\"outline-link-H4605992\">- Electroconvulsive therapy</a></li><li><a href=\"#H86405662\" id=\"outline-link-H86405662\">- Other options</a></li></ul></li><li><a href=\"#H1614170480\" id=\"outline-link-H1614170480\">Severe anxiety or insomnia</a></li></ul></li><li><a href=\"#H1828161573\" id=\"outline-link-H1828161573\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H13500325\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H116932847\" id=\"outline-link-H116932847\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PSYCH/14647|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PSYCH/91106\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for manic episode</a></li><li><a href=\"image.htm?imageKey=PSYCH/91107\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for hypomanic episode</a></li><li><a href=\"image.htm?imageKey=PSYCH/91398\" class=\"graphic graphic_table\">- DSM-5 diagnostic criteria for bipolar major depression</a></li><li><a href=\"image.htm?imageKey=PSYCH/82533\" class=\"graphic graphic_table\">- Adverse effects of antipsychotic meds</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antiseizure-drugs-mechanism-of-action-pharmacology-and-adverse-effects\" class=\"medical medical_review\">Antiseizure drugs: Mechanism of action, pharmacology, and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-and-lithium-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-assessment-and-diagnosis\" class=\"medical medical_review\">Bipolar disorder in adults: Assessment and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-choosing-pharmacotherapy-for-acute-mania-and-hypomania\" class=\"medical medical_review\">Bipolar disorder in adults: Choosing pharmacotherapy for acute mania and hypomania</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-clinical-features\" class=\"medical medical_review\">Bipolar disorder in adults: Clinical features</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-indications-for-and-efficacy-of-electroconvulsive-therapy-ect\" class=\"medical medical_review\">Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy (ECT)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-adults-psychoeducation-and-other-adjunctive-maintenance-psychotherapies\" class=\"medical medical_review\">Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-pregnant-women-treatment-of-major-depression\" class=\"medical medical_review\">Bipolar disorder in pregnant women: Treatment of major depression</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-women-contraception-and-preconception-assessment-and-counseling\" class=\"medical medical_review\">Bipolar disorder in women: Contraception and preconception assessment and counseling</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-in-women-preconception-and-prenatal-maintenance-pharmacotherapy\" class=\"medical medical_review\">Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=first-generation-antipsychotic-medications-pharmacology-administration-and-comparative-side-effects\" class=\"medical medical_review\">First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=folic-acid-supplementation-in-pregnancy\" class=\"medical medical_review\">Folic acid supplementation in pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-epilepsy-and-pregnancy\" class=\"medical medical_review\">Management of epilepsy and pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medical-consultation-for-electroconvulsive-therapy\" class=\"medical medical_review\">Medical consultation for electroconvulsive therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=open-neural-tube-defects-risk-factors-prenatal-screening-and-diagnosis-and-pregnancy-management\" class=\"medical medical_review\">Open neural tube defects: Risk factors, prenatal screening and diagnosis, and pregnancy management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-electroconvulsive-therapy-ect-for-adults\" class=\"medical medical_review\">Overview of electroconvulsive therapy (ECT) for adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-the-basics\" class=\"medical medical_basics\">Patient education: Bipolar disorder (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bipolar-disorder-manic-depression-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Bipolar disorder (manic depression) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reducing-the-costs-of-medicines-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Reducing the costs of medicines (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=reducing-the-costs-of-medicines-the-basics\" class=\"medical medical_basics\">Patient education: Reducing the costs of medicines (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacotherapy-for-schizophrenia-side-effect-management\" class=\"medical medical_review\">Pharmacotherapy for schizophrenia: Side effect management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=risks-associated-with-epilepsy-and-pregnancy\" class=\"medical medical_review\">Risks associated with epilepsy and pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=second-generation-antipsychotic-medications-pharmacology-administration-and-side-effects\" class=\"medical medical_review\">Second-generation antipsychotic medications: Pharmacology, administration, and side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=severe-antenatal-unipolar-major-depression-treatment\" class=\"medical medical_review\">Severe antenatal unipolar major depression: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-bipolar-disorder\" class=\"medical medical_society_guidelines\">Society guideline links: Bipolar disorder</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=technique-for-performing-electroconvulsive-therapy-ect-in-adults\" class=\"medical medical_review\">Technique for performing electroconvulsive therapy (ECT) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=teratogenicity-pregnancy-complications-and-postnatal-risks-of-antipsychotics-benzodiazepines-lithium-and-electroconvulsive-therapy\" class=\"medical medical_review\">Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy</a></li></ul></div></div>","javascript":null}